Funds distributed by the OoR


The School of Medicine's new Strategic Plan includes a new annual award cycle - the Translational Team Science (TTS) Award- administered in partnership with NC TraCS.  This award is aimed at capitalizing on the "culture of collaboration" at UNC Chapel Hill to foster new synergistic interdisciplinary teams of basic science and clinical investigators.  The award is not restricted to human subjects and tissues, and proposals may include research using cellular and animal model systems; however the project should translate across basic and clinical disciplines.

There are multiple stages of TTS applications and awards (see application process, below).  After submission of an initial one page Concept paper, selected teams will be invited to submit a full Feasibility proposal for review.  If awarded, TTS Phase I Feasibility grants will provide a 6-month period to begin to fully engage team members in the development of a competitive continuation proposal for TTS Phase II (2 years). Advancement to the next award stage is contingent on the merit of the proposed plan and progress in the prior period. The expectation is that these awards will provide the planning time and initial funds to support early stage denovo research teams that would otherwise not be possible.  This would ultimately lead to submission of novel interdisciplinary program project grants and multiple PI R01s by UNC SOM investigators.

TTSA awards will be made jointly with NC TraCS pilot funding. For teams led by  SOM PIs, the SOM will provide the funding match for TraCS funds.  For other teams led by non-SOM PIs, matched funds should be provided by other appropriate units.  Review of phase I and phase II applications (defined below) will be done by the NC TraCS review panel with equal consideration for early to late stage translational studies.

The inaugural TTSA RFA was issued in October 2013.    A summary of the teams and project are listed below.

Concept proposals will be accepted for the current cycle through December 8, 2015. Please see the TTSA RFP for a description of the program and guidelines for submission.

TTSA Phase I Award Teams- April 2015

Toni Darville, MD (Pediatrics), Scott Randell, PhD (Cell Biology and Physiology), Uma Nagarajan PhD (Pediatrics), Catherine O’Connell PhD (Pediatrics), Pris Wyrick PhD (Pediatrics), Mehmet Kesimer PhD (Biochemistry and Biophysics), Adrienne Cox PhD (Pharmacology), Kim Boggess, MD (Ob Gyn) and Matthew Zerden, MD (Ob Gyn).
Primary human fallopian tube cell models for research on Chlamydia trachomatis -
induced disease.

Richard F. Loeser, Jr., MD (Medicine), Pauline Kay Lund, PhD (Cell Biology and Physiology), M. Andrea Azcarate-Peril, PhD (Cell Biology and Physiology),  Joann Jordan, MD, MPH (Medicine/Rheumatology), Ryan Balfour Sartor, MD (Medicine), Todd A. Schwartz, DrPH (Biostatistics), Jenny P. Ting, PhD (Genetics).
The Role of the Microbiome in Osteoarthritis

Francisco A. Sylvester, MD (Pediatrics), Ian Carroll PhD (Medicine), Kinh N. Truong, PhD (Biostatistics).
Effects of a dysbiotic intestinal microbiome present in Crohn disease on skeletal health and linear growth

TTSA Phase I Award Teams- September 2014

Evan Dellon, MD, MPH (Medicine), Michael Kulis, PhD (Pediatrics  ), Brian Vickery, MD  (Pediatrics)
A novel T-cell directed approach to dietary therapy in patients with eosinophilic esophagitis
(Awarded Phase II in April 2015)

James Faber, PhD (Cell and Molecular Physiology), David Huang, MD (Neurology), William Powers, MD (Neurology), Yueh Lee, MD, PhD (Radiology), Kirk Wilhelmsen, MD (Genetics)
GENEtic Determinants of Collateral Status in Stroke - The GENEDCSS Study

David Gerber, MD (Surgery), Jude Samulski, PhD (Pharmacology), Caibin Cui, PhD (Medicine), Chengwen Li, PhD (Pediatrics)
Patient-derived chimeric mouse models for studying liver disease

Penny Gordon-Larsen, PhD (Nutrition), Barry Popkin, PhD (Nutrition), Annie Green-Howard, PhD (Biostatistics), Amanda Thompson, PhD (Anthropology)
Gut microbiome markers of cardiometabolic disease in transition to a Western diet
(Awarded Phase II in April 2015)

Brian Jensen, MD (Medicine), Gary Johnson, PhD (Pharmacology), Cary Anders, MD (Medicine), Sean Gomez, PhD (BME/Pharmacology), Joel Parker, PhD (Genetics)
Integrated profiling of the kinome and transcriptome to predict cardiotoxicity of kinase inhibitors

Kristy Richards, MD (Medicine), Dirk Dittmer, PhD (Microbiology and Immunology), David Suter, VMD, PhD, MS (NCSU)
Disrupting EBV lymphomagenesis as a novel strategy for the treatment of human and canine lymphoma

TTSA Phase I Award Teams- January 2014

James Bear, PhD (Cell Biology and Physiology), David Rubenstein, MD, PhD (Dermatology), Donna A. Culton, MD, PhD (Dermatology)
Accelerating cutaneous wound healing through inhibition of O-GlcNAc transferase

Mohanish Deshmukh, PhD (Cell Biology and Physiology), Charles Cairns, MD (Emergency Medicine), Praveen Sethupathy, PhD (Genetics), Ned Sharpless, MD (Medicine and Genetics)
miR-29 as a Novel Biomarker and Regulator of Aging

Flavio Frohlich PhD (Psychiatry) and Haewon Shin MD (Neurology)
Discovering the Mechanisms of Targeted Enhancement of Brain Activity and Cognition by BrainStimulation using Intracranial Electrophysiology in Epilepsy Patients

Yueh Z. Lee, MD, PhD (Radiology), Otto Zhou, PhD (Physics & Astronomy), Jianping Lu, PhD (Physics & Astronomy), Marianne Muhlebach, MD (Pediatric Pulmonology), Scott Donaldson, MD (Pulmonary Medicine), Jennifer Goralski, MD (Pulmonary Medicine), Richard Boucher, MD (Pulmonary Medicine), Katherine Birchard MD (Radiology), Casey Sams, MD (Radiology), Lynn Fordham(Radiology)

Stationary Chest Tomosynthesis for Imaging Young Cystic Fibrosis Patients
(Awarded Phase II in October 2014)

P. Kay Lund, PhD (Cell Biology and Physiology), Ric Boucher, MD (Pulmonary Medicine), Scott Randell, PhD (Cell Biology and Physiology),  Scott Magness, PhD (Cell Biology and Physiology), Evan Dellon, MD, MPH (Gastroenterology), Shengli Ding, PhD (Cell Biology and Physiology), Raluca Dumitru,  PhD (Genetics), Martina Gentzsch, PhD (Cell Biology and Physiology)
Intestinal epithelial cell culture systems to advance personalized research and therapy in Cystic Fibrosis (CF) and other gastrointestinal (GI) diseases
(Awarded Phase II in October 2014)

Shehzad Sheikh, MD (Gastroenterology) and Terry Furey, PhD (Genetics)
Identifying Genetic- and Microbial-based Molecular Markers of Inflammatory Bowel Disease

Maureen Su, MD (Microbiology and Immunology),Mike Cohen, MD (Infectious Disease), George Fedoriw, MD (Pathology), Terry Magnuson, PhD (Genetics), Jason Whitmire, PhD (Genetics)
Histone modifications in the clearance of chronic viral infections
(Awarded Phase II in October 2014)


    The OoR can assist departments and centers with startup and retention packages, but never funds the full package.  Chairs and Center Directors should make requests for these funds as early in the process as possible.  OoR contribution: 25% of the package, up to $100,000.  The OoR's contribution will be disbursed to the department over 2 or 3 years.  If you need to request startup or retention funds, contact the Office of Research.


    Bridge funding applications are accepted 3 times during the academic year: October, January and May.  A memo is sent to Chairs and Center Directors to share with their faculty giving specific due dates.  Generally the memo is sent out about 3 weeks before the due date.  Eligibility criteria:

    • The grant has been reviewed and received a written critique
    • The PI has no more than 2 active R01s or the equivalent level of funding
    • The does not have additional sources of lab support, e.g. trust fund
    • If the grant's NIH number identifies the grant as a 'new' grant, the PI must include a cover letter explaining how the new grant is a repackaged version of previously funded research
    • The department/center agrees to match the funding from the Dean's Office.

    The application for bridge funding much include:

    • current 3-4 page NIH biosketch
    • research section of the original grant application
    • the NIH review of that application
    • a draft rebuttal for the revised application
    • proposed budget for the bridge funds.

    Applications for or questions about bridge funding should be emailed to

    The  next round of proposals will be reviewed in  January 2016.  


    The Core Facilities Advocacy Committee [CFAC] is responsible for disbursing emergency and equipment funds for Core Facilities.  Emergency funds can be used for assistance with salaries and service contracts, purchase of small equipment needs [~$5-25K] and methodology development.  Equipment funds can be used for the purchase of instruments ranging from $30-100K and for cost-share amounts in conjunction with instrumentation grants.  The CFAC collects emergency requests in April/May for the coming fiscal year, but requests will be considered throughout the year as funds allow.  Equipment requests are opened in July, due in August and reviewed in September.